Key Drivers
- Gross Margin
- Cash Weakness
- Balance Sheet
AIAI Summary
TDOC should now be viewed as a high-risk turnaround, not a broken growth name, with any upside dependent on management proving sustained free cash flow and margin discipline through cost cuts and international growth while the core U.S. business still shrinks; until it delivers multiple quarters of positive FCF and stops lowering guidance, the stock looks like a distressed value bet rather than a clear re-rating opportunity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Weakness
- •Balance Sheet
TDOC still generates solid gross profit and has decent liquidity, but persistent operating losses, weak recent cash flow, and leverage/asset-quality risks outweigh its low sales and book valuation.
Price Behavior
Key Price Behavior Insights:
- •Higher-high setup
- •Post-peak pullback
- •Support retest
Over the last month, TDOC remains constructive after breaking above $6.00 and climbing to $7.25, but the pullback to $6.36 leaves $6.00-$6.10 as key support and $6.80-$7.25 as the zone needed to confirm the uptrend is resuming.
Sharp run-up to $7.25 may have left
Sentiment & News
Key News Insights:
- •Earnings miss
- •Lower guidance
- •BetterHelp weakness
Teladoc's Q1 beat on revenue but missed earnings and cut guidance, as cost cuts and international growth only partly offset weak BetterHelp demand, pressuring the stock.
The update points to continued near-term pressure on TDOC shares as investors stay focused on profitability and uneven demand trends
Similar Companies in Healthcare
Other companies in the same sector with AI ratings